Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TLC 388

Drug Profile

TLC 388

Alternative Names: Lipotecan; TLC-388; TLC388 HCl

Latest Information Update: 13 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Health Research Institutes; Taiwan Liposome Company
  • Class Antineoplastics; Camptothecins
  • Mechanism of Action Angiogenesis inhibitors; DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Neuroendocrine tumours; Rectal cancer
  • No development reported Solid tumours
  • Discontinued Renal cell carcinoma

Most Recent Events

  • 31 May 2019 Efficacy and adverse events data from a phase II trial in Neuroendocrine tumours presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 01 Dec 2018 National Health Research Institutes completes a phase II trial for Neuroendocrine tumours (Second-line therapy or greater) in Taiwan (IV) (NCT02457273)
  • 04 Nov 2018 Taiwan Liposome Company terminates a phase I/II trial for liver caner in Taiwan, as the study design could not support further development in this indication (IV) (NCT03035006)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top